1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1155/2017/3613505" target="_blank" rel="noreferrer noopener">http://doi.org/10.1155/2017/3613505</a>
Pages
3613505–3613505
Volume
2017
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.
Publisher
An entity responsible for making the resource available
Journal of immunology research
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
1905-07
Subject
The topic of the resource
*Cancer Vaccines/genetics/immunology/therapeutic use; Animal; Animals; Breast Neoplasms/genetics/immunology/prevention & control/therapy; CD8-Positive T-Lymphocytes/immunology; Cell Line; Cytotoxic/immunology; Disease Models; Disease Progression; Epitopes; erbB-2; Experimental/immunology/pathology/*prevention & control/*therapy; Female; Genes; Immunoglobulin G/blood; Inbred BALB C; Mammary Neoplasms; Mice; Neoplasm Metastasis/prevention & control; Proof of Concept Study; T-Lymphocyte/immunology; T-Lymphocytes; Tumor
Creator
An entity primarily responsible for making the resource
Rosenthal Ken S; Stone Sarah; Koski Gary; Zimmerman Daniel H
Description
An account of the resource
The prototype J-LEAPS T cell vaccine for HER-2/neu breast cancer (J-HER) consists of the murine HER-2/neu66-74 H-2(d) CD8 T cell epitope covalently attached through a triglycine linker to the J-immune cell binding ligand (ICBL) (human beta2 microglobulin38-50 peptide). The J-ICBL was chosen for its potential to promote Th1/Tc1 responses. In this proof-of-concept study, the ability of J-HER to prevent or treat cancer was tested in the TUBO cell-challenged BALB/c mouse model for HER-2/neu-expressing tumors. The J-HER vaccine was administered as an emulsion in Montanide ISA-51 without the need for a more potent adjuvant. When administered as a prophylactic vaccination before tumor challenge, J-HER protected against tumor development for at least 48 days. Despite eliciting protection, antibody production in J-HER-immunized, TUBO-challenged mice was less than that in unimmunized mice. More importantly, therapeutic administration of
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1155/2017/3613505" target="_blank" rel="noreferrer noopener">10.1155/2017/3613505</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Cancer Vaccines/genetics/immunology/therapeutic use
2017
Animal
Animals
Breast Neoplasms/genetics/immunology/prevention & control/therapy
CD8-Positive T-Lymphocytes/immunology
Cell Line
Cytotoxic/immunology
Disease Models
Disease Progression
Epitopes
erbB-2
Experimental/immunology/pathology/*prevention & control/*therapy
Female
Genes
Immunoglobulin G/blood
Inbred BALB C
Journal of immunology research
Koski Gary
Mammary Neoplasms
Mice
Neoplasm Metastasis/prevention & control
Proof of Concept Study
Rosenthal Ken S
Stone Sarah
T-Lymphocyte/immunology
T-Lymphocytes
Tumor
Zimmerman Daniel H